160 related articles for article (PubMed ID: 28693128)
1. Pediatric haematopoiesis and related malignancies.
Jin M; Xu S; An Q
Oncol Lett; 2017 Jul; 14(1):10-14. PubMed ID: 28693128
[TBL] [Abstract][Full Text] [Related]
2. The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study.
Mulrooney DA; Hyun G; Ness KK; Bhakta N; Pui CH; Ehrhardt MJ; Krull KR; Crom DB; Chemaitilly W; Srivastava DK; Relling MV; Jeha S; Green DM; Yasui Y; Robison LL; Hudson MM
Lancet Haematol; 2019 Jun; 6(6):e306-e316. PubMed ID: 31078468
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic haematopoietic stem cell transplantation for infant acute lymphoblastic leukaemia with KMT2A (MLL) rearrangements: a retrospective study from the paediatric acute lymphoblastic leukaemia working group of the Japan Society for Haematopoietic Cell Transplantation.
Kato M; Hasegawa D; Koh K; Kato K; Takita J; Inagaki J; Yabe H; Goto H; Adachi S; Hayakawa A; Takeshita Y; Sawada A; Atsuta Y; Kato K
Br J Haematol; 2015 Feb; 168(4):564-70. PubMed ID: 25302748
[TBL] [Abstract][Full Text] [Related]
5. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
[TBL] [Abstract][Full Text] [Related]
6. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
[TBL] [Abstract][Full Text] [Related]
7. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
Versluis J; Hazenberg CL; Passweg JR; van Putten WL; Maertens J; Biemond BJ; Theobald M; Graux C; Kuball J; Schouten HC; Pabst T; Löwenberg B; Ossenkoppele G; Vellenga E; Cornelissen JJ;
Lancet Haematol; 2015 Oct; 2(10):e427-36. PubMed ID: 26686044
[TBL] [Abstract][Full Text] [Related]
8. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
Shin HJ; Kim HJ; Sohn SK; Min YH; Won JH; Kim I; Yoon HJ; Lee JH; Jo DY; Joo YD; Jung CW; Lee KH; ; Chung JS; Ahn JS; Kim SJ; Lee JH; Choi SJ; Lee JH; Bae SH; Hong DS; Zang DY; Kim SH; Lee JL; Bang SM
Jpn J Clin Oncol; 2010 Jun; 40(6):556-66. PubMed ID: 20185460
[TBL] [Abstract][Full Text] [Related]
9. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.
Sant M; Minicozzi P; Mounier M; Anderson LA; Brenner H; Holleczek B; Marcos-Gragera R; Maynadié M; Monnereau A; Osca-Gelis G; Visser O; De Angelis R;
Lancet Oncol; 2014 Aug; 15(9):931-42. PubMed ID: 25030467
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of beta-catenin discriminates acute myeloid leukaemia from acute lymphoblastic leukaemia.
Serinsöz E; Neusch M; Büsche G; Wasielewski R; Kreipe H; Bock O
Br J Haematol; 2004 Aug; 126(3):313-9. PubMed ID: 15257703
[TBL] [Abstract][Full Text] [Related]
11. Leukaemia and myeloid malignancy among people exposed to low doses (<100 mSv) of ionising radiation during childhood: a pooled analysis of nine historical cohort studies.
Little MP; Wakeford R; Borrego D; French B; Zablotska LB; Adams MJ; Allodji R; de Vathaire F; Lee C; Brenner AV; Miller JS; Campbell D; Pearce MS; Doody MM; Holmberg E; Lundell M; Sadetzki S; Linet MS; Berrington de González A
Lancet Haematol; 2018 Aug; 5(8):e346-e358. PubMed ID: 30026010
[TBL] [Abstract][Full Text] [Related]
12. Acute leukaemia and myelodysplastic syndromes with chromosomal rearrangement involving 11q23 locus, but not
Zuo W; Wang SA; DiNardo C; Yabe M; Li S; Medeiros LJ; Tang G
J Clin Pathol; 2017 Mar; 70(3):244-249. PubMed ID: 27496968
[TBL] [Abstract][Full Text] [Related]
13. The Cape Town experience with haematopoietic stem cell transplantation: the paediatric programme.
Roux P; Novitzky N
S Afr Med J; 2000 Aug; 90(8):804-11. PubMed ID: 11022631
[TBL] [Abstract][Full Text] [Related]
14. Strategies for reducing the treatment-related physical burden of childhood acute myeloid leukaemia - a review.
Hasle H; Kaspers GJ
Br J Haematol; 2017 Jan; 176(2):168-178. PubMed ID: 27766626
[TBL] [Abstract][Full Text] [Related]
15. Advances in childhood leukaemia: successful clinical-trials research leads to individualised therapy.
Ziegler DS; Dalla Pozza L; Waters KD; Marshall GM
Med J Aust; 2005 Jan; 182(2):78-81. PubMed ID: 15651967
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic approaches to haematological malignancies in adolescents and young adults.
Place AE; Frederick NN; Sallan SE
Br J Haematol; 2014 Jan; 164(1):3-14. PubMed ID: 24007213
[TBL] [Abstract][Full Text] [Related]
17. From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia.
Jakobsen NA; Vyas P
Clin Med (Lond); 2018 Apr; 18(Suppl 2):s47-s53. PubMed ID: 29700093
[TBL] [Abstract][Full Text] [Related]
18. High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia.
Steckel NK; Groth C; Mikesch JH; Trenschel R; Ottinger H; Kordelas L; Mueller-Tidow C; Schliemann C; Reicherts C; Albring JC; Silling G; Schmidt E; Berdel WE; Lenz G; Ditschkowski M; Beelen DW; Stelljes M
Br J Haematol; 2018 Mar; 180(6):840-853. PubMed ID: 29468631
[TBL] [Abstract][Full Text] [Related]
19. Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis.
Canaani J; Beohou E; Labopin M; Ghavamzadeh A; Beelen D; Hamladji RM; Niederwieser D; Volin L; Markiewicz M; Arnold R; Mufti G; Ehninger G; Socié G; Kröger N; Mohty M; Nagler A
J Intern Med; 2019 Apr; 285(4):407-418. PubMed ID: 30372796
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
